摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-二甲氧基苯氧基)哌啶 | 420137-19-5

中文名称
4-(2-二甲氧基苯氧基)哌啶
中文别名
4-(2-二乙氧基苯氧基)哌啶
英文名称
4-(2-ethoxy-phenoxy)-piperidine
英文别名
4-(2-Ethoxyphenoxy)piperidine
4-(2-二甲氧基苯氧基)哌啶化学式
CAS
420137-19-5
化学式
C13H19NO2
mdl
MFCD08061063
分子量
221.299
InChiKey
IPOFRRUDIUKVAL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    322.4±32.0 °C(Predicted)
  • 密度:
    1.041±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.538
  • 拓扑面积:
    30.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:de35f09b018b5b365fa9ffb8679825b9
查看

文献信息

  • [EN] NEW BENZOYL UREA DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'UREE BENZOYLE
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2006010966A1
    公开(公告)日:2006-02-02
    The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C1-C4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkoxy, aroyl-carbamoyl optionally substituted with halogen atom or C1-C4 alkyl or C1-C4 alkoxycarbonyl group, or the neighboring X and Y groups optionally form together with one or more identical or different additional hetero atom and -CH= and/or -CH2- groups an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably morpholine, pyrrole, pyrrolidine, oxo- or thioxo-pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazolidine, oxo- or thioxo-imidazole or imidazolidine, 1,4-oxazine, oxazole, oxazolidine, triazole, oxo- or thioxo-oxazolidine, or 3-oxo-l,4-oxazine ring, V and Z independently are hydrogen or halogen atom, cyano, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl, hydroxy or optionally esterized carboxyl group, W is oxygen atom, as well as C1-C4 alkylene, C2-C4 alkenylene, aminocarbonyl, -NH-, -N(alkyl)-, -CH2O-, -CH2S-, -CH(OH)-, -OCH2- group, wherein the meaning of alkyl is a C1-C4 alkyl group -, when the dotted bonds ( --- ) represent simple C-C bonds then U is hydroxy group or hydrogen atom or when W is C1-C4 alkylene or C2-C4 alkenylene group, then one of the dotted bonds ( --- ) can represent a further double C-C bond and in this case U means an electron pair, which participate in the double bond and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor. Furthermore objects of the present invention are the pharmaceutical compositions containing new benzoyl urea derivatives of formula (I) or optical antipodes or racemates or the salts thereof as active ingredients and processes for producing these compounds and pharmaceutical compositions.
    公式(I)的新苯甲酰生物,其中X和Y的含义独立地是氢原子、羟基、苄氧基、基、硝基、C1-C4烷基磺酰胺(可选择地与卤原子或卤原子取代)、C1-C4烷酰胺(可选择地与卤原子或卤原子取代)、C1-C4烷氧基、芳酰基-基(可选择地与卤原子或C1-C4烷基或C1-C4烷氧羰基团取代)或相邻的X和Y基团可选择地与一个或多个相同或不同的额外杂原子和-CH=和/或-CH2-基团一起形成一个可选择地取代的4-7成员同源或异源环,优选为吗啡啉、吡咯吡咯烷、氧代或吡咯烷、吡唑吡唑烷、咪唑咪唑烷、氧代或咪唑咪唑烷、1,4-氧杂噁啉、氧唑、氧杂噁啉、三唑、氧代或代氧杂噁啉或3-氧代-1,4-氧杂噁啉环,V和Z独立地是氢或卤原子、基、C1-C4烷基、C1-C4烷氧基、三甲基、羟基或可选择酯化的羧基,W是氧原子,以及C1-C4烷基、C2-C4烯基、基羰基、-NH-、-N(烷基)-、- O-、- S-、-CH(OH)-、-O -基团,其中烷基的含义是C1-C4烷基群-,当虚线键(---)代表简单的C-C键时,U是羟基或氢原子,或当W是C1-C4烷基或C2-C4烯基群时,那么虚线键(---)中的一个可以代表进一步的双键C-C键,在这种情况下,U表示参与双键和光学异构体、消旋体及其盐的电子对,这些化合物是NMDA受体的高效和选择性拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。此外,本发明的目的是包含公式(I)的新苯甲酰生物、光学异构体或消旋体或其盐为活性成分的药物组合物,以及生产这些化合物和药物组合物的方法。
  • [EN] AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDIQUES COMME ANTAGONISTES DU RECEPTEUR NMDA
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2002034718A1
    公开(公告)日:2002-05-02
    The invention relates to new NR2B selective NMDA receptor antagonist carboxylic acid amide derivatives of formula (I) as well as the recemates, optical antipodes and the salts thereof formed with acids and bases. Fruthermore objets of the present invention are the pharmaceutical compositions containing compounds of formula (I) or the salts thereof as active ingredients, as well as the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the method of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
    本发明涉及公式(I)的新型NR2B选择性NMDA受体拮抗剂羧酸酰胺衍生物,以及与酸和碱形成的外消旋体,光学对映体和其盐。此外,本发明的目标是含有公式(I)化合物或其盐作为活性成分的制药组合物,以及公式(I)化合物的合成,以及含有这些化合物的药物的化学和制药制造,以及使用这些化合物的治疗方法,即向待治疗的哺乳动物(包括人类)施用本发明的化合物的有效量/量,作为药物或单独使用。本发明的新型羧酸酰胺衍生物的公式(I)是高效和选择性的NMDA受体拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
  • Benzoyl Urea Derivatives
    申请人:Borza Istvan
    公开号:US20090170901A1
    公开(公告)日:2009-07-02
    The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C 1 -C 4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C 1 -C 4 alkanoylamido optionally substituted with a halogen atom or halogen atoms, C 1 -C 4 alkoxy, aroyl-carbamoyl optionally substituted with halogen atom or C 1 -C 4 alkyl or C 1 -C 4 alkoxycarbonyl group, or the neighboring X and Y groups optionally form together with one or more identical or different additional hetero atom and —CH═ and/or —CH 2 — groups an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably morpholine, pyrrole, pyrrolidine, oxo- or thioxo-pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazolidine, oxo- or thioxo-imidazole or imidazolidine, 1,4-oxazine, oxazole, oxazolidine, triazole, oxo- or thioxo-oxazolidine, or 3-oxo-1,4-oxazine ring, V and Z independently are hydrogen or halogen atom, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy or optionally esterized carboxyl group, W is oxygen atom, as well as C 1 -C 4 alkylene, C 2 -C 4 alkenylene, aminocarbonyl, —NH—, —N(alkyl)-, —CH 2 O—, —CH 2 S—, —CH(OH)—, —OCH 2 — group, wherein the meaning of alkyl is a C 1 -C 4 alkyl group—, when the dotted bonds ( ) represent simple C—C bonds then U is hydroxy group or hydrogen atom or when W is C 1 -C 4 alkylene or C 2 -C 4 alkenylene group, then one of the dotted bonds ( ) can represent a further double C—C bond and in this case U means an electron pair, which participate in the double bond and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor. Furthermore objects of the present invention are the pharmaceutical compositions containing new benzoyl urea derivatives of formula (I) or optical antipodes or racemates or the salts thereof as active ingredients and processes for producing these compounds and pharmaceutical compositions.
    公式(I)中的新苯甲酰生物,其中X和Y的含义独立地为氢原子,羟基,苄氧基,基,硝基,C1-C4烷基磺酰胺,可选地被卤素原子或卤素原子取代,C1-C4酰胺基,可选地被卤素原子或卤素原子取代,C1-C4烷氧基,芳酰基,可选地被卤素原子或C1-C4烷基或C1-C4烷氧羰基基团取代,或相邻的X和Y基团可选地与一个或多个相同或不同的额外杂原子和-CH═和/或-CH2-基团一起形成可选地取代的4-7成员同源或异源环,优选为吗啉,吡咯咪啉,氧-或代-咪啉,吡唑吡唑啉,咪唑咪唑啉,氧-或代-咪唑咪唑啉,1,4-噁唑啉,噁唑噁唑啉,三唑,氧-或代-噁唑啉,或3-氧代-1,4-噁唑环,V和Z独立地为氢或卤素原子,基,C1-C4烷基,C1-C4烷氧基,三甲基,羟基或可选的酯化羧基,W为氧原子,以及C1-C4烷基,C2-C4烯基,基羰基,-NH-,-N(烷基)-,- O-,- S-,-CH(OH)-,-O -基团,其中烷基的含义是C1-C4烷基,当点状键()表示简单的C-C键时,U为羟基或氢原子,或当W为C1-C4烷基或C2-C4烯基时,点状键()中的一个可以表示进一步的双重C-C键,在这种情况下,U表示参与双键的电子对和光学对映体,外消旋体和其盐是高效和选择性的NMDA受体拮抗剂,此外,大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。此外,本发明的目标是含有公式(I)的新苯甲酰生物、光学对映体或外消旋体或其盐作为活性成分的药物组合物,以及制备这些化合物和药物组合物的过程。
  • AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS
    申请人:RICHTER GEDEON VEGYESZETI GYAR R.T.
    公开号:EP1328514A1
    公开(公告)日:2003-07-23
  • NEW BENZOYL UREA DERIVATIVES
    申请人:RICHTER GEDEON VEGYESZETI GYAR RT.
    公开号:EP1771429A1
    公开(公告)日:2007-04-11
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯